Company: NCEL
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001213900-25-104162
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-10-30
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 9)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)</div>

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:

<div align='center'>☒ Form 20-F ☐ Form 40-F

CONTENTS</div>

Completion of Merger Transaction

On October 30, 2025 (the
“Closing Date”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS” or
the “Company”), completed the previously announced transaction with Kadimastem Ltd., an Israeli company
(“Kadimastem”), pursuant to the Agreement of Merger and Plan of Reorganization, dated as of November 4, 2024, and as
amended from time to time (the “Merger Agreement”), by and among the Company, Kadimastem and NLS Pharmaceutics (Israel)
Ltd., an Israeli company and a wholly owned subsidiary of the Company (the “Merger”).

In connection with the Merger,
the Registrant effected a 1-for-10 reverse stock split of the Company’s common shares, preferred shares and preferred participation
certificates (the “”). The transactions contemplated by the Merger Agreement (including the Merger
and the Reverse Stock Split) were approved by the Company’s shareholders at the extraordinary general meeting of shareholders held
on September 29, 2025.

As part of the closing of
the Merger, holders of common shares, preferred shares, preferred certificates and warrants of NLS at the time of the Merger also received
contingent value rights with respect to future net proceeds, if any, from the disposition of certain legacy assets of the Company (including
Mazindol ER, but excluding the DOXA platform).

Further, in connection with
the Merger, the Company changed its name to “